Kadri A
France
Research Article
The Complete Study of the Switch from Iron-Sucrose Originator to Iron-
Sucrose Similar and Vice Versa in Hemodialysis Patients
Author(s): Rottembourg J, Guerin A, Diaconita M and Kadri ARottembourg J, Guerin A, Diaconita M and Kadri A
Aim: To describe and compare the hematological parameters and anemia medications used in chronic kidney disease (CKD) patients undergoing hemodialysis (HD), before and after switching between the Iron-Sucrose originator (IS), and an Iron-Sucrose Similar (ISS). Methods: An observational single-center longitudinal study comparing the impact of changing from the original intravenous IS (Venofer®), to an ISS (Fer Mylan®), then back to the original IS. The analysis compares retrospective data from three consecutive 26-week IS treatment periods (P1, P2, and P3), versus a prospective 26-week ISS period (P4), followed by a further 26-week prospective period using the original IS (P5). Hemoglobin (Hb) was assessed every two weeks, while serum ferritin, transferrine saturation (TSAT), and C-reactive protein (CRP) were collected twice per period. ESA (darbepo.. View More»
